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This phase I multicenter study was aimed at assessing the feasibility and safety of intravenous administration
of third party bone marrowederived mesenchymal stromal cells (MSC) expanded in platelet lysate in 40
patients (15 children and 25 adults), experiencing steroid-resistant grade II to IV graft-versus-host disease
(GVHD). Patients received a median of 3 MSC infusions after having failed conventional immunosuppressive
therapy. A median cell dose of 1.5  106/kg per infusion was administered. No acute toxicity was reported.
Overall, 86 adverse events and serious adverse events were reported in the study, most of which (72.1%) were
of infectious nature. Overall response rate, measured at 28 days after the last MSC injection, was 67.5%, with
27.5% complete response. The latter was signiﬁcantly more frequent in patients exhibiting grade II GVHD as
compared with higher grades (61.5% versus 11.1%, P ¼ .002) and was borderline signiﬁcant in children as
compared with adults (46.7 versus 16.0%, P ¼ .065). Overall survival at 1 and 2 years from the ﬁrst MSC
administration was 50.0% and 38.6%, with a median survival time of 1.1 years. In conclusion, MSC can be safely
administered on top of conventional immunosuppression for steroid resistant GVHD treatment. Eudract
Number 2008-007869-23, NCT01764100.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION Mesenchymal stromal cells (MSCs), a pluripotent cell popu-
Graft-versus-host disease (GVHD) is a severe and poten-
tially life-threatening complication after hematopoietic stem
cell transplantation (HSCT) [1]. Around 50% of patients
exhibiting GVHD are expected not to beneﬁt from conven-
tional treatment with steroids [2]. Although awide variety of
second-line treatments for these patients are available, the
prognosis for these patients remains dismal because of
higher risk of infectious complications, immunosuppression-
mediated toxicity, and often incomplete GVHD remission
[3,4]. The development of a better treatment strategy for
steroid resistant GVHD, therefore, represents a key factor to
achieve improved long-term survival for HSCT recipients.dgments on page 380.
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13.11.033lation [5], are endowed with broad immunosuppressive ac-
tivity [6] and have been reported to be effective for GVHD
treatment [7-9]. The present prospective, multicenter, phase
I study was aimed at assessing the feasibility and safety of
platelet lysate (PL)eexpanded, third party, bone marrow
(BM)ederived MSCs administration for the treatment of
steroid resistant GVHD in adult and pediatric patients. Sec-
ondary aims were to assess the efﬁcacy of such an approach
on top of conventional immunosuppression, the response to
treatment, and the overall survival (OS) in the whole cohort.
MATERIALS AND METHODS
Patients
Patients exhibiting acute or chronic, steroid-resistant or -dependent,
grade II to IV GVHD were eligible for the study. Histopathology to conﬁrm
clinical diagnosis of GVHD was encouraged but not required to enter the
study. GVHD was graded according to the Seattle-Glucksberg modiﬁed
criteria for acute forms [10] and to the National Institutes of Health
consensus criteria for chronic cases [11]. In the acute GVHD setting, steroid
resistance was deﬁned as lack of clinical improvement after 5 days ofTransplantation.
Table 1
Patients Characteristics
Patients Characteristics Adults
n ¼ 25
Children
n ¼ 15
Overall
n ¼ 40
Age at MSC, median (range), yr 40.5 (19-65) 4.6 (1-18) 27.8 (1-65)
Sex
Male 16 (64) 11 (73) 27 (68)
Female 9 (36) 4 (27) 13 (33)
Disease type
Malignant 23 (92) 13 (87) 36 (90)
Nonmalignant 2 (8) 2 (13) 4 (10)
Remission state at SCT*
Complete remission 12 (52) 9 (69) 21 (58)
Partial nonremission 11 (48) 4 (31) 15 (42)
Conditioning regimen
Reduced intensity 12 (60) 5 (33) 17 (43)
Fully myeloablative 8 (40) 10 (67) 18 (45)
Donors
MFD 7 (28) 1 (7) 8 (20)
MUD 11 (44) 10 (67) 21 (53)
MMD 7 (28) 4 (27) 11 (28)
Stem cells source
PB 18 (72) 2 (13) 20 (50)
BM 5 (20) 10 (67) 15 (38)
CB 2 (8) 3 (20) 5 (12)
GVHD prophylaxis
CSAþMTX 4 (16) 0 (0) 4 (10)
CSAþMTXþATG 12 (48) 10 (67) 22 (55)
Other 9 (36) 5 (33) 14 (35)
GVHD grading
Acute 19 (76) 12 (80) 31 (77)
Grade II 2 (8) 9 (60) 11 (27)
Grade III-IV 17 (68) 3 (20) 20 (50)
Chronic (severe) 2 (8) 1 (7) 3 (8)
Overlap 4 (16) 2 (13) 6 (15)
Organ involvement
Single organ 9 (36) 7 (47) 16 (40)
Multi organ 16 (64) 8 (53) 24 (60)
MSC indicates mesenchymal stromal cells; SCT, stem cell transplantation;
MFD, matched familiar donor; MUD, matched unrelated donor; MMD,
mismatched donor; PB, peripheral blood; BM, bonemarrow; CB, cord blood;
GVHD, graft-versus-host disease; CSA, cyclosporine A; MTX, methotrexate;
ATG, antithymocyte globulin.
Data presented are n (%) unless otherwise indicated.
* For malignancies only.
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gression of at least 1 grade within 3 days from steroid onset. For chronic
GVHD, steroid resistance was deﬁned as absence of clinical improvement
after 30 days of treatment and steroid dependence as more than 2 episodes
of GVHD reﬂaring after steroid tapering (less than 1 mg/kg daily).
This protocol has been authorized by the National Authorities for Phase
I trials (Istituto Superiore di Sanità, ISS) with protocol number 70524
(08)-PRE.21-959 (Eudract Number 2008-007869-23) and approved by local
ethical committees or institutional review boards of the participating
centers. Donors and patients, or their legal guardians, gavewritten informed
consent. The study was registered at the ofﬁcial NIH site www.clinical
trials.gov under the number NCT01764100.
MSC Production
MSCs were derived from BM of unrelated, third party, HLA-mismatched
donors. MSCs were produced starting from the washouts of discarded BM
bags and expanded with PL, as already described [12]. Brieﬂy, sealed bags
and ﬁlters from BM harvests were washed with sterile solution to recover
cells. MSCs were isolated and ex vivo expanded in the presence of Modiﬁed
Eagles Medium supplemented with 5% human PL, according to identical
standard operative procedures at the 2 production centers. The 2 MSC
producing cell factories (Laboratorio di Terapia Cellulare “G. Lanzani” in
Bergamo and Laboratorio di Terapia Cellulare “S. Verri” in Monza) had
received formal approval by Agenzia Italiana del Farmaco (AIFA, Rome, Italy)
to operate according to European good manufacturing practice regulations
for the production of sterile, injectable drugs of small volumes. These 2 cell
factories provided MSCs for all centers taking part in the study. The delivery
system was organized in such a way that each participating center could
receive MSCs within 48 to 72 hours from request.
Before distribution, the MSC bags had to satisfy all the release criteria,
including absence of gram positive and negative bacteria, absence of fungi
and mycoplasma, endotoxin level below < 5 EU/kg, absence of spontaneous
growth in semisolid media, absence of cytogenetic lesions in more than 20
metaphases, as well as > 80% viability and > 70% positivity for CD73, CD90,
and CD105, and < 10% contamination by CD14, CD34, and CD45 hemato-
poietic cells. The ﬁnal product fulﬁlled the international recognized criteria
to be declared “bona ﬁde” MSC [5].
MSC Administration
MSCs were injected intravenously through a central line. The cells were
thawed immediately before infusion, paracetamol and antihistamine were
pre-emptively administered to avoid acute reactions, and patients were
monitored for 2 hours after receiving MSCs. Hence, MSC administration did
not require admittance to the transplantation unit; thus, improving the
patients quality of life and reducing the treatment costs. MSCs were infused
on top of the ongoing immune suppression therapy given for GVHD.
A minimum of 2 MSC infusions was recommended with about 5 to
7 days of interval between them. Each MSC infusion aimed at reaching
1  .5  106 cells/kg of recipient body weight. Further MSC administrations
could be provided upon request of the treating physician. The tapering or
increase of conventional immunosuppressive therapy after MSC adminis-
tration was also left to the clinical judgment of the treating teams.
Response to treatment was evaluated on day þ28 after the last MSC
infusion or at date of death if earlier than day þ28. Complete response (CR)
was deﬁned as absence of signs and symptoms of GVHD, partial response
(PR) as GVHD decrease of at least 1 grade as compared with day 0, and no
response as no change in GVHD scoring. Patients were considered to have
responded to treatment if exhibiting either PR or CR. Transplantation-
related mortality (TRM) included all deaths associated with HSCT except
those related to original disease recurrence.
MSC safety was assessed by monitoring the infusion tolerability, by
analyzing complete blood count and biochemistry for the entire week after
MSC administration, and by recording adverse events (AE) and serious
adverse events (SAE) occurring up to 30 days after the last MSC infusion
through speciﬁc case report forms. AE and SAEwere graded according to the
Common Terminology Criteria for Adverse Events, Version 4.
Statistical Analysis
The comparison between treatment response rates in different groups
was performed by means of the Fisher’s exact test. Results are expressed as
proportion of success, and the corresponding 95% conﬁdence intervals (CI)
were calculated using the Wilson method. The incidence of GVHD recur-
rence in patients with response was estimated from the date of response
assessment, accounting for death as competing event.
Survival was deﬁned as the time from the date of ﬁrst MSC infusion to
death from any cause. Survival curves were estimated with the Kaplan-
Meier method, whereas the log-rank test was applied to compare the sur-
vival of different groups. The incidence of TRM was also estimated,considering deaths due to disease progression as competing events. Follow-
up was updated as of October 2013.
The analyses were carried out using SAS 9.3, all the tests were per-
formed 2-sided with a signiﬁcance level of .05.RESULTS
Patients’ Characteristics
Between August 2009 and April 2012, 40 patients (25
adults, 15 children) were enrolled and treated according to
the present protocol in 5 Italian centers: 17 adults at the USC
Hematology of the “Azienda Ospedaliera Papa Giovanni
XXIII”, Bergamo, 14 children at the Pediatric Department of
the “Ospedale San Gerardo dei Tintori” in Monza, 6 at the
Adult Hematology Division of the “Ospedale San Gerardo dei
Tintori” in Monza, 2 adults at the Hematology Unit of the
“Ospedale Generale” in Bolzano, and 1 child at the Pediatric
Department of “Ospedale Regionale” in Padova. Only 1 pa-
tient received MSC for an acute GVHD (aGVHD) deﬁned as
progressive in the ﬁrst 3 days of steroid treatment, 35 pa-
tients exhibited GVHD not responding to steroid treatment
after at least 5 days of administration, and 4 patients were
deﬁned as affected by steroid-dependent GVHD.
Patients’ characteristics as well as transplantation and
GVHD details are summarized in Table 1. Of note, the inci-
dence of acute mild GVHD (ie, grade II) at study entry was
Table 2
Safety of MSC Treatment in Adults and Children
Characteristic Adults n ¼ 25 Children n ¼ 15 Overall n ¼ 40
Patients with
No events 3 (12.0) 3 (20.0) 6 (15.0)
At least an AE 13 (52.0) 5 (33.3) 18 (45.0)
At least a SAE 9 (36.0) 7 (47.7) 16 (40.0)
Total no. of events 51 35 86
Type
AE 38 (74.5) 26 (74.3) 64 (74.4)
SAE 13 (25.5) 9 (25.7) 22 (25.6)
Grade
II 24 (47.0) 22 (62.9) 46 (53.5)
III-IV 27 (53.0) 13 (37.1) 40 (46.5)
Nature
Infections 37 (72.5) 25 (71.4) 62 (72.1)
Other 14 (27.5) 10 (28.6) 24 (27.9)
MSC indicates mesenchymal stromal cells; AE, adverse event; SAE, serious
adverse event.
Data presented are n (%).
Events are graded according to the Common Terminology Criteria for
Adverse Events, Version 4.0.
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(60.0% versus 8.0%, P ¼ .0001), the latter exhibiting an acute
grade III to IV GVHD in 68.0% of the cases. The distribution
between single organ or multiple organ GVHD involvement
was similar between children and adults; multiple organ
presentation being predominant overall (60.0% versus 40.0%
single organ presentation, P ¼ .61). In the pediatric popula-
tion, skin was the most commonly affected organ (14 of 15
patients), whereas adults mostly exhibited gut involvement
either alone (7 of 25 patients) or in combinationwith skin or
liver involvement (18 of 25 patients) (Table S1).
All patients underwent steroid treatment as ﬁrst line of
immunosuppression against GVHD. Children received MSC
as second line of treatment directly after steroids more often
than adults (80.0% versus 20.0%, P ¼ .0003). GVHD in adults
was resistant to 2 to 6 lines of immunosuppression before
receiving MSC in 80.0% of the cases (data not shown).
Feasibility and Toxicity
A total of 158 MSC infusions were administered to 40
patients; each patient receiving a median number of 3 in-
fusions (ranges, 2 to 7 for children and 2 to 11 for adults).
Patients received a median of 1.5  106/kg (range, .8 to 3.1)
MSCs per dose, with no difference between adults and
children, thus the target cell dose was achieved in all pa-
tients (data not shown). Median time of MSC administra-
tion was 13 days (range, 4 to 277) and 35 (range, 5 to 1535)
from GVHD diagnosis, for children and adults respectively,
and median treatment duration was 14 days for adultsTable 3
Treatment Response of Adults and Children According to GVHD Type and Grading
GVHD Adults Children
CR CRþPR CR
Acute
II 2 of 2 (100) 2 of 2 (100) 4 of 9 (44
III-IV 2 of 17 (11.8) 13 of 17 (76.5) 1 of 3 (33
Chronic severe* 0 of 2 (0) 0 of 2 (0) 0 of 1 (0)
Overlapy 0 of 4 (0) 2 of 4 (50) 2 of 2 (10
Total 4 of 25 (16.0) 17 of 25 (68.0) 7 of 15 (46
GVHD indicates graft-versus-host disease; CR, complete response; PR, partial resp
Data presented are n (%).
* The 3 chronic severe GVHD were all grade III.
y The 6 overlap were grade II (2 children) and grade III (4 adults).(range, 3 to 206) and 15 for children (range, 4 to 28),
respectively (data not shown). No side effects/adverse re-
actions were documented during and immediately after
MSC infusion.
Complete blood counts as well as standard biochemistry
(serum creatinine, bilirubin, aspartate aminotransferase, al-
bumin, lactate dehydrogenase and glucose), as analyzed for 7
consecutive days after MSC infusion for the ﬁrst 32 enrolled
patients, did not show relevant changes (Table S2).
Thirty-four out of 40 patients (22 adults and 12 children)
showed a total of 64 reported AE and 22 SAE after 74.7
person-months of observation, with a rate of AE and SAE of .9
and .3 per person-month, as described in Table 2 and detailed
in Table S3. The seriousness for adverse events was assigned
in 13 cases to life-threatening situations, and in 9 cases, to
the need for hospitalization. Of all reported events, 72.1%
were due to viral, bacterial, or fungal infections, followed by
multiple organ failures due to GVHD progression (6.9%)
(Table S2). AE and SAE were equally distributed among pa-
tients independently from age and GVHD characteristics at
study entry. Of the reported events, 46.5% were grades III to
IV in severity. Seventy percent of all events resolved without
sequelae.
Response to MSC Administration
Overall, 27 out of 40 patients (67.5%) showed a GVHD
response 28 days after the last MSC infusion: 11 (27.5%)
exhibiting a CR (4 adults and 7 children) and 16 (40.0%)
exhibiting a PR (13 adults and 3 children) to treatment
(Table 3). No response was observed in 3 cases of chronic
classic severe GVHD, whereas 2 CR were observed in 2 chil-
dren (grade II) and 2 PR were observed in 4 adults (grade III)
with overlapping syndrome (Table 3).
The results of the univariate analysis evaluating the as-
sociation between patient characteristics at study entry and
treatment response, assessed both as CR and CRþPR, are
illustrated in Table 4. Grade II GVHD, as compared with
higher grading, showed a statistically signiﬁcant better
chance of achieving a CR (61.5% versus 11.1%, P ¼ .002).
Overall response rates did not differ between adults and
children (68.0% versus 66.7%, P ¼ 1.00), even if the rate of CR
was higher in children as compared with adults (46.7%
versus 16.0%, P ¼ .065), probably due to the different severity
of the clinical presentations in these 2 groups.
In addition, we found that patients responding to MSC
were not different in terms of underlying disease (malignant
66.7% versus nonmalignant 75%, P ¼ .60), conditioning
regimen (myeloablative 66.7% versus reduced-intensity
69.2%, P ¼ 1.00), donor type (matched 72.4% versus mis-
matched 60%, P¼ .67), and stem cell source (peripheral bloodOverall
CRþPR CR CRþPR
.4) 7 of 9 (77.7) 6 of 11 (54.5) 9 of 11 (81.2)
.3) 1 of 3 (33.3) 3 of 20 (15) 14 of 20 (70)
0 of 1 (0) 0 of 3 (0) 0 of 3 (0)
0) 2 of 2 (100) 2 of 6 (33.3) 4 of 6 (66.7)
.7) 10 of 15 (66.7) 11 of 40 (27.5) 27 of 40 (67.5)
onse.
Table 4
Univariate Analysis of Treatment Response
CR n (%) 95% CI P Value CRþPR n (%) 95% CI P Value
Overall 11 of 40 (27.5) 16.1-42.8 27 of 40 (67.5) 52.0-79.9
MSC doses 1.000 .305
2-3 7 of 24 (29.2) 14.9-49.2 18 of 24 (75.0) 55.1-88.0
>3 4 of 16 (25.0) 10.2-49.5 9 of 16 (56.3) 33.2-76.9
Patient type .065 1.000
Children 7 of 15 (46.7) 24.8-69.9 10 of 15 (66.7) 41.7-84.8
Adults 4 of 25 (16.0) 6.4-34.6 17 of 25 (68.0) 48.4-82.8
GVHD type 1.000 .120
Acute 9 of 31 (29.0) 16.1-46.6 23 of 31 (74.2) 56.8-86.3
Chronic-overlap 2 of 9 (22.2) 6.3-54.7 4 of 9 (44.4) 18.9-73.3
GVHD grade .002 .157
II 8 of 13 (61.5) 35.5-82.3 11 of 13 (84.6) 57.8-95.7
III-IV 3 of 27 (11.1) 3.9-28.1 16 of 27 (59.3) 40.7-75.5
No. organs involved .473 .177
1 3 of 16 (18.8) 6.6-43.0 13 of 16 (81.2) 57.0-93.4
2 8 of 24 (33.3) 18.0-53.3 14 of 24 (58.3) 38.8-75.5
IS Lines .153 .333
MSC as second line 7 of 17 (41.2) 21.6-64.0 13 of 17 (76.5) 52.7-90.4
MSC > second line 4 of 23 (17.4) 7.0-37.1 14 of 23 (60.9) 40.8-77.8
Days from GVHD onset to MSC* .709 .157
<30 d 7 of 23 (30.4) 15.6-50.9 18 of 23 (78.3) 58.1-90.3
>30 d 3 of 15 (20) 7.0-45.2 8 of 15 (53.3) 30.1-75.2
CR indicates complete response; PR, partial response; MSC, mesenchymal stem cell; IS, immunosuppression; CI; conﬁdence interval; GVHD, graft-versus-host
disease.
* Two patients have date of GVHD onset missing.
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of previous immune suppression treatments and the number
of MSC infusions did not inﬂuence the overall and CR rate in
our population. A trend was seen in relation to timing be-
tween GVHD onset and MSC administration; overall
response being more favorable for patients receiving MSC
within 30 days from GVHD onset (78.3% versus 53.3%,
P ¼ .157) (data not shown).
The subsequent analysis on the 27 responders
(Supplementary Table 1) indicates that most of the overall
and complete responders were found in the subgroups of
patients showing isolated skin involvement (CRþPR, 87.5%),
or isolated gut involvement (CRþPR, 85.7%), whereas the
liver involvement was linked to a worst percentage of com-
plete (21.4%) and partial (50%) responses.
The ongoing immune suppression treatments of these
patients, on top of which MSCs were given, are detailed in
Table 5. In particular, in 14 patients, the dose of steroids
remained unchanged and in 10 it was tapered, whereas in 6
patients other drugs were added. In 3 patients, all immune
suppressants were stopped before response evaluation.
Finally, we investigated the evolution of GVHD in the 27
responding patients.We found that chronic GVHD developed
in 11 (7 PR and 4 CR, 8 adults and 3 children) of the 27 re-
sponders. Taking into account death as a competing event,
the cumulative incidence of chronic GVHD, was 37% at six
months with only 1 event developing after 1 year from
response (Figure 1).
Survival
With a median follow-up of 2.8 years from the ﬁrst MSC
infusion and of 3.7 from SCT, the 1 and 2-year overall survival
rates of this cohort of patients were 50 and 38%, respectively,
whereas the median survival time was of 1.1 years. Nine
patients died before reaching the time of clinical response
assessment after a median of 28 days from the ﬁrst MSC. At
last follow-up, 16 out of 40 patients were alive with no evi-
dence of GVHD in 12 of them. Of the 2 components of mor-
tality, TRM was the most relevant, as shown in Figure 2A.Eighteen patients died from TRM: GVHD itself (n ¼ 11), in-
fections (n ¼ 5), organ failure (n ¼ 1), and hemorrhage
(n ¼ 1). Six patients died after relapsing from their original
malignant disease. A better survival was seen in patients
with grade II GVHD (P ¼ .0482) and a trend for a better
outcome was seen in patients younger than 18 years (P ¼
.2035) (Figure 2B,C).
DISCUSSION
The present prospective study underlines the feasibility of
a cell therapyebased treatment of pediatric and adult pa-
tients with steroid resistant GVHD using third party, PL-
expanded BM-derived MSCs. The study was conducted
within the context of academic institutions to provide direct
evidence of at least a similar clinical effect as compared to
what was reported from 2004 onward by other groups of
investigators using MSCs expanded using fetal calf serum
[9,13-17]. The primary objective of our study was to assess
the safety of PL-MSC infusions given on the top of conven-
tional immunosuppression therapy. Only 1 report on a very
small group of patients has been published so far on PL-
expanded BM-derived MSCs [18] and, therefore, our study
is the ﬁrst extended phase I toxicity study performed with
cells expanded in the absence of animal-derived reagents. As
in previous reports with MSCs [19], in our study no imme-
diate or late clinical or laboratory relevant toxic events could
be attributed to MSC infusions. Therefore, we can conﬁrm
that PL-MSCs can be administered safely in both adults and
children.
The relationship between MSC infusion and infections
was a matter of concern since von Bahr et al. reported an
increased number of infectious complications in the ﬁrst
2 years after MSC administration, with an infection related
mortality as high as 54% [20]. In our study, we also report a
high rate of infectious episodes, but this is likely not to be
different when compared with an historical group of control
patients treated with conventional immunosuppressive
therapy [21]. Remarkably, in our experience, the infection-
related mortality affected only 10% of our patients.
Table 5
Details for Concomitant Treatments in Responder Patients
UPN GVHD Grading
at Enrollment
Ongoing Therapy at Enrollment Ongoing Therapy at
Response Evaluation
Response
(GVHD Grading)
101 II Steroid Steroid tapering Complete (0)
102 II Steroid Mycophenolate mofetil Complete (0)
Steroid tapering
103 II Steroid Steroid tapering Partial (I)
105 II Steroid Steroid tapering Partial (I)
106 III Steroid Steroid tapering Partial (II)
Mycophenolate mofetil Mycophenolate mofetil
Etanercept
107 II Steroid Steroid tapering Complete (0)
108 III Steroid Etanercept Steroid unchanged Partial (II)
109 II Steroid Steroid Partial (I)
Mycophenolate mofetil
112 II Steroid Steroid tapering Complete (0)
113 II Steroid Steroid tapering Complete (0)
Mycophenolate mofetil
114 II Steroid Steroid tapering Complete (0)
116 III Steroid Etanercept Steroid tapering Complete (0)
201 III Steroid Etanercept Steroid unchanged Partial (II)
Etanercept
Mycophenolate mofetil
202 III Steroid Steroid unchanged Partial (II)
203 III Steroid Mycophenolate mofetil Steroid unchanged Partial (II)
204 II Steroid Steroid unchanged Complete (0)
Mycophenolate mofetil Mycophenolate mofetil
306 IV Steroid None Partial (III)
307 III Steroid Steroid unchanged Partial (II)
Pentostatin
308 III Steroid Pentostatin None Partial (II)
310 III Steroid Pentostatin Steroid unchanged Partial (II)
312 III Steroid Pentostatin Steroid unchanged Partial (II)
313 IV Steroid Pentostatin Steroid unchanged Partial (I)
314 III Steroid Steroid unchanged Complete (0)
315 II Steroid Cyclosporine A None Complete (0)
316 III Steroid Pentostatin Steroid unchanged Complete (0)
317 III Steroid Pentostatin Steroid unchanged Partial (II)
501 IV Steroid Pentostatin Steroid unchanged Partial (III)
GVHD indicates graft-versus-host disease; UPN, unique patient number.
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be observed in steroid refractory aGVHD with any different
second line treatment, as recently conﬁrmed by Alousi et al.,
who showed a range from 44% to 62% of severe infectiousFigure 1. Cumulative incidence of GVHD and death post response, for the 27
patients who responded to MSC. The estimates are reported at 1 and 2 years
from response assessment with standard errors (se).complications observed after 4 different second lines of
treatment for aGVHD [22]. Another possible drawback of an
excessive immunosuppression might have been an increased
rate of leukemia relapse [23]. In contrast to this possibility, in
our study, the underlying disease recurred only in 6 patients,
who were all at high risk of disease relapse because of poor
remission status at transplantation. Finally, no evidence of
heterotopic tissue formation was documented, conﬁrming
what observed in all the other clinical reports with MSCs
[7,8,24,25].
Evaluation of efﬁcacy of PL-MSC was the secondary
objective of this study, but it is worth mentioning that, in
more than 60% of our patients, a PR or CR was observed.
Although other studies reported a higher CR rate, we provide
evidence that 38% of our patients were alive at 2 years from
the ﬁrst MSC administration. These encouraging results ob-
tained in mostly adult patients and with an appropriate
prolonged period of follow-up are indeed at least compara-
ble with those reported by the Swedish group [26].
When comparing responders (CR þ PR) versus non-
responders, a signiﬁcant difference was found in measured
plasma levels of IL2R-alpha (lower in responders) (Figure S1),
suggesting the possible role of this test as a marker for MSC
response evaluation, as already previously investigated by
our group [27]. This, however, still remains to be validated in
future prospective studies.
Beyond all these positive results, our study highlights
some possible limits of this therapeutic approach. In our
Figure 2. Survival and cumulative incidence of death by cause of death for the 40 treated patients. Cumulative incidence of death by cause, for the 40 treated patients,
and overall survival by groups. (2A) Shows cumulative incidence of death for the study cohort (40 patients) is represented. Transplantation-related mortality (TRM)
and relapse incidence are detailed as speciﬁc cause of death. The estimates are reported at 1 and 2 years with standard errors (se). (2B) Shows overall survival from
the ﬁrst MSC administration is presented for the enrolled patients, as speciﬁed for GVHD grading at study entry. The estimates are reported at 1 and 2 years with
standard errors (se). (2C) Shows overall survival from the ﬁrst MSC administration is presented for the enrolled patients, as speciﬁed for adult and pediatric patients.
The estimates are reported at 1 and 2 years with standard errors (se).
M. Introna et al. / Biol Blood Marrow Transplant 20 (2014) 375e381380experience, GVHD grading was the only predictor of treat-
ment response and no additional independent factor was
detected in the multivariable analysis. Therefore, for most
adult patients with the highest grade of GVHD and, therefore,
the highest need of an effective therapy, this treatment
program was largely unsatisfactory. In addition, our study
illustrates that among responders, the risk of developing
chronic GVHD remains, suggesting the need of further
treatment to avoid this late complication.
All in all, our results indicate that a further optimization of
the clinical use of PL-MSC is needed. Possible example of
such an optimization could be represented by the use of
higher cell doses, the sequential or combined administration
of PL-MSC with other second line treatments. Alternatively,
the use of MSCs derived from different organs (eg, umbilical
cord wall), possibly able to express a higher immune sup-
pressive activity, could also be considered [28].In conclusion, the present study conﬁrms the feasibility
and safety of treatment with third party PL-expanded BM-
derived MSCs, which may offer some clinical beneﬁt. Further
studies are needed to support this approach as a reliable
therapeutic tool and to address the largely unmet clinical
needs of patients with steroid refractory severe GVHD.
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